Introduction
Granulocyte/monocyte adsorptive apheresis (GMA) is a safe induction therapy for ulcerative colitis (UC) and is often used in combination with other induction therapies; however, its additive benefit when combined with biologics has not been fully evaluated.
Aims & Methods
We conducted a multicenter retrospective study using the IBD registry of Nagoya University and its affiliated hospitals (the INSIGHT study). Patients with UC who initiated infliximab (IFX) or vedolizumab (VDZ) between 2014 and 2024 were included. The week-14 clinical remission (CR) rates were compared between patients treated with and without concomitant GMA during induction therapy using propensity score matching (PSM). Factors associated with week-14 CR for each biologic were also analyzed. CR was defined as PRO2 ≤1 and a rectal bleeding score of 0. Concomitant GMA was defined as initiation of GMA within 8 weeks after starting biologic therapy.
Results
A total of 270 IFX-treated and 175 VDZ-treated patients were included, of whom 43 (15.9%) and 18 (10.3%), respectively, received concomitant GMA. The mean number of GMA sessions was 7.0 in the IFX group and 6.5 in the VDZ group, and the proportion receiving intensive GMA was 93% and 100%, respectively. In the IFX cohort, the combination group had significantly more steroid-refractory patients and showed lower albumin levels and higher CRP and SCCAI scores. In the overall IFX cohort, the week-14 CR rates were 52.4% in the combination group and 51.2% in the non-combination group; after excluding 35 patients who were already in clinical remission at induction, the corresponding rates were 50.0% and 48.2%, respectively. After PSM, there were no significant differences in week-14 CR or CRP remission rates. In the VDZ cohort, the combination group also had significantly more steroid-refractory patients and showed lower albumin levels and higher MES, CRP, and SCCAI scores. In the overall VDZ cohort, the week-14 CR rates were 44.4% in the combination group and 43.3% in the non-combination group; among 146 patients excluding those already in clinical remission at induction, the corresponding rates were 44.4% and 35.9%, respectively. After PSM, the combination group showed better outcomes in week-14 CR (P=0.065) and CRP remission rate (P=0.049). Independent predictors of week-14 CR were prior TNF exposure (OR 0.32, P<0.01) and higher SCCAI score (OR 0.83, P<0.01) in the IFX cohort, and higher SCCAI score (OR 0.78, P<0.01) in the VDZ cohort.
Conclusion
Higher SCCAI scores were associated with poorer outcomes in both IFX- and VDZ-treated patients, and GMA was combined in patients with higher disease activity. Although no additive benefit of concomitant GMA was observed in IFX-treated patients, the week-14 remission induction rate was better in VDZ-treated patients receiving concomitant GMA.